Pregabalin Open Access Articles

Pregabalin is a structural analogue of gamma-aminobutyric acid (GABA). It acts by presynaptic binding to the α -2-λ subunit of voltage-gated calcium channels that are widely distributed in the spinal cord and brain. This mechanism in pre and post-synaptic membranes leads to inhibition of excitatory neurotransmitters release. Compared with gabapentin, pregabalin due to its better fat solubility and transmission in blood-brain barrier is a more favorable replacement for this drug, with better pharmacokinetic properties and because of less hepatic metabolism, drug interactions are lower with pregabalin. Pregabalin in the treatment of neuropathic pain, incisional pain, aches and inflammatory pain induced by formalin has been used effectively. Open access to the scientific literature means the removal of barriers (including price barriers) from accessing scholarly work. There are two parallel “roads” towards open access: Open Access articles and self-archiving. Open Access articles are immediately, freely available on their Web site, a model mostly funded by charges paid by the author (usually through a research grant). The alternative for a researcher is “self-archiving” (i.e., to publish in a traditional journal, where only subscribers have immediate access, but to make the article available on their personal and/or institutional Web sites (including so-called repositories or archives)), which is a practice allowed by many scholarly journals. Open Access rises practical and policy questions for scholars, publishers, funders, and policymakers alike, including what the return on investment is when paying an article processing fee to publish in an Open Access articles, or whether investments into institutional repositories should be made and whether self-archiving should be made mandatory, as contemplated by some funders.

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024